HomepageGNLX • NASDAQ
add
Genelux Corp
$ 2,96
Na sluitingstijd:(4,73%)-0,14
$ 2,82
Gesloten: 9 mei, 20:00:00 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 2,85
Dag-range
$ 2,69 - $ 3,05
Jaar-range
$ 1,60 - $ 5,89
Beurswaarde
111,70 mln. USD
Gem. volume
188,29K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 7,82 mln. | -3,78% |
Netto inkomsten | -7,49 mln. | 4,56% |
Netto winstmarge | — | — |
Winst per aandeel | -0,21 | 27,59% |
EBITDA | -7,76 mln. | 3,41% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 35,10 mln. | 78,85% |
Totale activa | 38,98 mln. | 57,99% |
Totale passiva | 9,14 mln. | -4,72% |
Totaal aandelenvermogen | 29,85 mln. | — |
Uitstaande aandelen | 37,73 mln. | — |
Koers-boekwaardeverhouding | 3,61 | — |
Rendement op activa | -53,02% | — |
Rendement op kapitaal | -65,38% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -7,49 mln. | 4,56% |
Operationele kasstroom | -5,44 mln. | -24,83% |
Kasstroom uit beleggingen | 3,51 mln. | 307,51% |
Kasstroom uit financiering | 9,57 mln. | 1.290,55% |
Nettomutatie in liquide middelen | 7,64 mln. | 242,64% |
Vrije kasstroom | -4,19 mln. | -220,46% |
Over
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Opgericht
2001
Hoofdvestiging
Website
Werknemers
24
